
zzso of P zzso zzso in clinical zzso has had limited zzso zzso factors have included the limitation in our understanding of the zzso in which zzso zzso is mechanistically important in clinical drug zzso the failure to prove that zzso of zzso achieved in patients were sufficient to inhibit zzso and the inability to zzso prove that zzso zzso was occurring in zzso in zzso New approaches are needed to determine the clinical settings in which zzso zzso plays a major role in zzso zzso trials with third generation zzso are zzso including trials with the compounds zzso zzso and zzso Using the zzso zzso zzso zzso as an imaging agent, increased zzso has been seen in normal liver and kidney after administration of zzso zzso zzso and zzso These studies confirm that the zzso of zzso achieved in patients are able to increase zzso of a zzso zzso Furthermore, zzso cells obtained from patients treated with zzso zzso demonstrate enhanced zzso retention in an ex zzso zzso after administration of the zzso Finally, a subset of patients treated with zzso zzso show enhanced zzso retention in zzso zzso These results suggest that zzso zzso can increase drug zzso in zzso zzso and normal zzso in zzso Using third generation zzso zzso and properly designed clinical trials, it should be possible to determine the contribution of zzso to the reversal of clinical drug zzso 

